Jamuway Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 16-11-2024
- Paid Up Capital ₹ 0.40 M
as on 16-11-2024
- Company Age 11 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.99 M
as on 16-11-2024
- Revenue 12.15%
(FY 2023)
- Profit 81.58%
(FY 2023)
- Ebitda 47.19%
(FY 2023)
- Net Worth 8.72%
(FY 2023)
- Total Assets -20.36%
(FY 2023)
About Jamuway Pharmaceuticals
The Corporate was formerly known as Jamuway Pharmaceutical & Crop Protection Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.40 M.
The company currently has active open charges totaling ₹2.99 M.
Rajesh Varma and Vimal Kumawat serve as directors at the Company.
- CIN/LLPIN
U24230GJ2013PTC075062
- Company No.
075062
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 May 2013
- Date of AGM
28 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Surat, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Jamuway Pharmaceuticals Private Limited offer?
Jamuway Pharmaceuticals Private Limited offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Nutritional Supplements.
Who are the key members and board of directors at Jamuway Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajesh Varma  | Director | 14-May-2013 | Current |
| Vimal Kumawat | Director | 12-May-2015 | Current |
Financial Performance of Jamuway Pharmaceuticals.
Jamuway Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 12.15% increase. The company also saw a substantial improvement in profitability, with a 81.58% increase in profit. The company's net worth moved up by a moderate rise of 8.72%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Jamuway Pharmaceuticals?
In 2023, Jamuway Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bank Of India Creation Date: 10 Jun 2020 | ₹0.49 M | Open |
Bank Of India Creation Date: 15 Mar 2016 | ₹2.50 M | Open |
How Many Employees Work at Jamuway Pharmaceuticals?
Jamuway Pharmaceuticals has a workforce of 13 employees as of Mar 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Jamuway Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Jamuway Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
